Aktuellt
SENASTE
Redeye see a Q3 2023 report from Nanologica that came in lower than we had projected in terms of sales, however, it aligned nicely with our EBIT estimate due to lower costs. With the first deliveries to Asia already shipped, we anticipate an eventful period ahead.
LÄS MER
